In patients with cardiometabolic , and reduced the risk of hospitalization for…
Published on 31 Aug 2025
In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.
#ESCCongress #WCCardio
Originally posted on LinkedIn by JAMA · View the original post